Largest prospective observational registry in locally advanced basal cell carcinoma   Extrapolated analysis on 433 laBCC patients from the largest of the 3 cohorts included in the full analysis

patients with newly diagnosed, HHI-naive laBCC (without BCCNS)* follow-up, with a median duration of 25.4 months (range 0.16–39.56) for cohort 1 US centers Treatment patterns and associated effectiveness and safety in real-world settings

Erivedge® demonstrated efficacy in the real-world setting

Parameters used to determine response assessment

Factors primarily dictating initial treatment choices Number and size of tumours Extent of involvement Histopathology Anatomic location of BCC lesions Erivedge®-treated patients had:   higher prevalence of high-risk clinical features (multiple or larger lesions (>20 mm)   considerations of disfigurement and potentially higher risk of recurrence after surgery (e.g. periocular, paranasal or scalp regions)

Safety profile of Erivedge® was manageable and similar to that reported in trials Most common AEs:

Ageusia/dysgeusia (71 patients; 61.7%) Muscle spasms (66 patients; 57.4%) Alopecia (58 patients; 50.4%) Weight loss (29 patients; 25.2%)

The effectiveness and safety of Erivedge® in the real-world setting was consistent with that observed in clinical trials populations despite the fact that the RegiSONIC study was inclusive of patients with comorbidities, older age and poor performance status

Click here to access the full publication

Please see full prescribing information for additional important safety information

*Of the 433 patients, 115 (26.6%) were included in the vismodegib group, 251 (58.0%) in the non-vismodegib treatment group, and 67 (15.5%) in the observation group (no treatment within 90 days of enrollment). †Among 101 efficacy-evaluable patients. AE, adverse event; BCC, basal cell carcinoma; BCCNS, basal cell carcinoma nevus syndrome; HHI, Hedgehog inhibitor; laBCC, locally advanced basal cell carcinoma. 1. Sekulic A, Yoo S, Kudchadkar R et al. Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry. PLoS One. 2022; 17 (1): e0262151.

M-XX-00018374